Current views on neurosarcoidosis: pathogenesis, clinical manifestations, diagnosis
https://doi.org/10.14412/2074-2711-2019-3-104-109
Abstract
The review gives data on the etiology, pathogenesis, and clinical manifestations of sarcoidosis, which are associated particularly with damage to the central and peripheral nervous system. Sarcoidosis is currently regarded as a genetically determined, polyetiologic, and multisystem, disease of mainly autoimmune origin, which is accompanied by a productive inflammatory response with the formation of space-occupying noncaseous granulomas. The detection rates for the classical forms of sarcoidosis of the lungs, lymph nodes, and eyes are increasing, while the intravital diagnosis of neurosarcoidosis is still difficult. The latter mimics many other neurological diseases, frequently in persistent disabling disorders and death. Studies focus on searching for imaging, biological and/or immune markers that can reliably diagnose this disease. The problem of small fiber neuropathy that is considered to be the most common and early manifestation of neurosarcoidosis is being actively studied. In 2018, Neurosarcoidosis Consortium Consensus Group (NCCG), USA, proposed the diagnostic criteria for neurosarcoidosis, which are presented in this article.
About the Authors
M. S. Pushkaryov
Saint Petersburg State University
Russian Federation
Russian Federation
Department of Neurosurgery and Neurology,
7–9, Universitetskaya Embankment, Saint Petersburg 199034
L. M. Tibekina
Saint Petersburg State University
Russian Federation
Russian Federation
Department of Neurosurgery and Neurology,
7–9, Universitetskaya Embankment, Saint Petersburg 199034
L. P. Churilov
Saint Petersburg State University
Russian Federation
Russian Federation
Laboratory of Autoimmunity Mosaic, Department of Pathology,
7–9, Universitetskaya Embankment, Saint Petersburg 199034
References
1. Werner W. Morbus Boeck. In: Lehrbuch der speziellen Pathologie. VEB G. Fischer Verlag; 1970. 137 p.
2. Suslina ZA, Kistenev BA, Maksimova MYu, Morgunov VA. Neirosarkoidoz [Neurosarcoidosis]. Moscow: MEDpress-inform; 2009. 208 p.
3. Arkema EV, Yvette YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018 Aug 24;9(11): 227-240. doi: 10.1177/2040622318790197. eCollection 2018 Nov.
4. Ungprasert P, Carmona EM, Utz JP, et al. Epidemiology of Sarcoidosis 1946–2013: A Population Based Study. Mayo Clin Proc. 2016 Feb;91(2):183-8. doi: 10.1016/j.mayocp.2015.10.024. Epub 2015 Dec 22.
5. Vizel' AA, Vizel' IYu, Amirov NB. Epidemiology of sarcoidosis in the Russian Federation. Vestnik sovremennoi klinicheskoi meditsiny. 2017;10(5): 66-73 (in Russ.).
6. Rossi G, Cavazza A, Colby TV. Pathology of Sarcoidosis. Clin Rev Allergy Immunol. 2015 Aug;49(1):36-44. doi: 10.1007/s12016-015-8479-6.
7. Shakhmuradova DA, Paleev NR, Gorenkov RV, Chereiskaya NK. Epidemiology of sarcoidosis. Zdorov'e i obrazovanie v XXI veke. 2007;9(4):391. (In Russ.).
8. Gerke AK. Morbidity and Mortality in Sarcoidosis. Curr Opin Pulm Med. 2014 Sep; 20(5):472-8. doi: 10.1097/MCP.0000000 000000080.
9. Celada LJ, Hawkins C, Drake WP. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Clin Chest Med. 2015 Dec;36(4): 561-8. doi: 10.1016/j.ccm.2015.08.001. Epub 2015 Sep 19.
10. Dzampaev AT. Neurological manifestations of neurosarcoidosis. Dis. cand. med. sci. Moscow; 2010. 111 p.
11. Ershov GA, Churilov LP. About the possible autoimmune nature of sarcoidosis: what autoantigens are involved and why? Klinicheskaya patofiziologiya. 2017;23(3):77-82. (in Russ.).
12. Musaelyan A, Lapin S, Nazarov V, et al. Vimentin as antigenic target in autoimmunity: A comprehensive review. Autoimmun Rev. 2018 Sep;17(9):926-934. doi: 10.1016/j.autrev.2018.04.004. Epub 2018 Jul 17.
13. Kinloch A, Kaiser Y, Wolfgeher D, et al. In Situ humoral immunity to Vimentin in hlaDrB1*03+ Patients With Pulmonary sarcoidosis. Front Immunol. 2018 Jul 9;9:1516. doi: 10.3389/fimmu.2018.01516. eCollection 2018.
14. Heinle R, Chang C. Diagnostic criteria for sarcoidosis. Autoimmun Rev. 2014 Apr-May; 13(4-5):383-7. doi: 10.1016/j.autrev.2014.01.035. Epub 2014 Jan 11.
15. Couture P, Brillet PY, Varin S, et al. Sarcoidosis in Patients with Antisynthetase Syndrome: Presentation and Outcome. J Rheumatol. 2018 Aug;45(9):1296-1300. doi: 10.3899/jrheum.171098. Epub 2018 Jul 1.
16. Bindoli S, Dagan A, Torres-Ruiz J, et al. Sarcoidosis and Autoimmunity: From Genetic Background to Environmental Factors. Isr Med Assoc J. 2016 Mar-Apr;18(3-4): 197-202.
17. Di Alberti L, Piattelli A, Artese L, et al. Human herpesvirus 8 variants in sarcoid tissues. Lancet. 1997 Dec 6;350(9092):1655-61.
18. Maeda H, Niimi T, Sato S, et al. Human herpesvirus 8 is not associated with sarcoidosis in Japanese patients. Chest. 2000 Oct;118(4):923-7.
19. Belec L, Mohamed AS, Lechapt-Zalcman E, et al. Lack of HHV-8 DNA sequences in sarcoid tissues of French patients. Chest. 1998 Sep; 114(3):948-9.
20. Sugaya M, Nakamura K, Takahiro W, et al. Human herpesvirus type 8 is not detected in cutaneous lesions of sarcoidosis. Br J Dermatol. 1999 Oct;141(4):769.
21. Dekonenko EP. Neurosarcoidosis. Nevrologicheskii zhurnal. 2002;(1):4-9. (In Russ.).
22. Agnihotri S, Singhal T, Stern B, Cho T. Neurosarcoidosis. Semin Neurol. 2014 Sep; 34(4):386-94. doi: 10.1055/s-0034-1390387. Epub 2014 Nov 4.
23. Stern BJ, Royal W, Gelfand JM, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis From the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018 Dec 1;75(12):1546- 1553. doi: 10.1001/jamaneurol.2018.2295.
24. Kimura H, Takeuchi J, Tsutada T, et al. A case of neurosarcoidosis with recurrent brainstem infarction, obstructive hydrocephalus and brainstem atrophy. Rinsho Shinkeigaku. 2018 Jul 27;58(7):445-450. doi: 10.5692/clinicalneurol.cn-001155. Epub 2018 Jun 30. 25. Maskery MP, Cooper PN, Pace A. Neurosarcoidosis associated with intracerebral haemorrhage: a challenge in diagnosis and management. Pract Neurol. 2018 Jun;18(3): 246-249. doi: 10.1136/practneurol-2017- 001794. Epub 2018 Jan 23.
25. Jachiet V, Lhote R, Rufat P, et al. Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis. J Neurol. 2018 Oct;265(10):2333-2341. doi: 10.1007/s00415-018-9001-x. Epub 2018 Aug 14.
26. Vargas A, Gorelick PB, Testai FD. Progressive central nervous system vasculopathy in sarcoidosis: A case report. J Neurol Sci. 2016 Mar 15;362:153-4. doi: 10.1016/j.jns.2016.01. 050. Epub 2016 Jan 23.
27. Maskery MP, Cooper PN, Pace A. Neurosarcoidosis associated with intracerebral haemorrhage: a challenge in diagnosis and management. Pract Neurol. 2018 Jun;18(3): 246-249. doi: 10.1136/practneurol-2017-001794. Epub 2018 Jan 23.
28. Kidd DP, McCabe DJ, Wilhelm T, et al. Carotid arteritis causing amaurosis fugax and ischaemic cerebrovascular events in neurosarcoidosis. Clin Neurol Neurosurg. 2018 Jun; 169:103-106. doi: 10.1016/j.clineuro.2018. 03.019. Epub 2018 Mar 22.
29. Siasos G, Paraskevopoulos T, Gialafos E, et al. Vascular function and ocular involvement in sarcoidosis. Microvasc Res. 2015 Jul;100:54-8. doi: 10.1016/j.mvr.2015.03.008. Epub 2015 Apr 29.
30. Bihan HG, Fysekidis M, Cohen R, et al. SarcoÏdose: l’atteinte des hormones a dependance antehypophysaire est insuffisamment diagnostiquee. La Presse Medicale. 2012;41(10): 524-9.
31. Nakao K, Noma K, Sato B, et al. Serum prolactin levels in eighty patients with sarcoidosis. Eur J Clin Invest. 1978 Feb;8(1):37-40.
32. Ali N, Kaledina EA, Petyaeva AV, et al. Hyperprolactinemia and autoimmunity. Klinicheskaya patofiziologiya. 2018:24(3):27-39. (In Russ.).
33. Chatani H, Tanaka M, Nagata T, et al. Guillain-Barre syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-Nacetylgalactosaminyl-GD1a antibody. J Clin Neurosci. 2014 Jan;21(1):170-2. doi: 10.1016/j.jocn.2013.01.015. Epub 2013 Jul 31.
34. Oldroyd A, Dawson, T, Nixon J. A case of neurosarcoidosis that presented with symptoms of Guillain–Barre syndrome. BMJ Case Rep. 2011 Apr 1;2011. pii: bcr0220113800. doi: 10.1136/bcr.02.2011.3800.
35. Sene D. Small fiber neuropathy: diagnosis, causes and treatment. Joint Bone Spine. 2018 Oct;85(5):553-559. doi: 10.1016/j.jbspin.2017.11.002. Epub 2017 Nov 16.
36. Levin TD, Saperstein DS. Routine use of punch biopsy to diagnose small fiber neuropathy in fibromyalgia patient. Clin Rheumatol. 2015 Mar;34(3):413-7. doi: 10.1007/s10067-014-2850-5. Epub 2014 Dec 24.
37. Lauria G, Merkies ISG, Faber CG. Small fiber neuropathy. Curr Opin Neurol. 2012 Oct; 25(5):542-9. doi: 10.1097/WCO.0b013e328 35804c5.
38. Levin OS, Dzampaev AT. Diagnostics and Treatment of Neurosarcoidosis. Al'manakh klinicheskoi meditsiny. 2006;(13):113-21. (In Russ.).
39. Hottenrott T, Dersch R, Berger B, et al. The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS. 2015 Dec 13;12:27. doi: 10.1186/s12987-015-0024-8.
40. Wengert O, Rothenfusser-Korber E, Vollrath B, et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci. 2013 Dec 15;335(1-2):124-30. doi: 10.1016/j.jns.2013.09.008. Epub 2013 Sep 11.
41. Jimenez-Bonilla JF, Gonzalez-Gay MA, Banzo I. Usefulness of 18F-FDG-PET/CT imaging in a patient with neurosarcoidosis. Med Clin (Barc). 2018 Dec 14;151(11):464-465. doi: 10.1016/j.medcli.2018.02.024. Epub 2018 Apr 21.
42. Gholamrezanezhad A, Mehta L. 18F-FDG PET/CT helps in unmasking the great mimicker: A case of neurosarcoidosis with isolated involvement of the spinal cord. Revista Espanola de Medicina Nuclear e Imagen Molecular. 2018; 37(3):172-4.
43. Chan M, Hsiao E. Neurosarcoidosis on FET and FDG PET/CT. Clin Nucl Med. 2017 Mar; 42(3):197-199. doi: 10.1097/RLU.000000000 0001516.
44. Khodarahmi I, Turbin RE, Frohman LP, Ghesani N. 18F-FDG Uptake in Neurosarcoid Dural Plaque on PET/CT. Clin Nucl Med. 2016 Sep;41(9):e410-1. doi: 10.1097/RLU.000000 0000001284.
45. Joubert B, Chapelon-Abric C, Biard L, et al. Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. JAMA Neurol. 2017 Nov 1;74(11):1336-1344. doi: 10.1001/ jamaneurol.2017.2492.
46. Gelfand J, Bradshaw M, Stern B, et al. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13.
47. Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J, et al. Anti-TNF-a; therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol. 2014 Mar-Apr;32(2): 275-84. Epub 2013 Dec 9.
48. Tavee JO, Karwa K, Ahmed Z, et al. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017 May;126:135-138. doi: 10.1016/j.rmed.2017.03.011. Epub 2017 Mar 9.
Review
For citations:
Pushkaryov M.S., Tibekina L.M., Churilov L.P. Current views on neurosarcoidosis: pathogenesis, clinical manifestations, diagnosis. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):104-109. (In Russ.) https://doi.org/10.14412/2074-2711-2019-3-104-109
Views: 418
Email this article 